Our studies to date of a large cohort of pancreatic cancer patients suggest that MMP3 staining may be useful as a prognostic tissue biomarker, and might be anticipated to predict response to therapies targeting this axis. The gene discussed is MMP3; the disease is familial pancreatic carcinoma.